India Glycols Limited Overview
India Glycols is a promoter-controlled Indian industrial and consumer conglomerate built around one core competence: converting agricultural feedstock (molasses and grain) into ethanol and then into higher-value outputs. Founded in 1983 and the first company globally to make ethylene oxide (EO) and mono-ethylene glycol (MEG) from renewable molasses-based ethanol (commercial since 1989), it historically ran four segments — Bio-based Specialities and Performance Chemicals (BSPC), Potable Spirits, Bio-Fuel and Ennature Biopharma — from three integrated sites at Kashipur, Gorakhpur and Dehradun. In FY26 it generated ₹9,827 Cr gross revenue, ₹4,211 Cr net revenue, ₹654 Cr EBITDA (15.5% margin) and ₹293 Cr PAT. Its "3x3" model (three ethanol sources feeding three outputs) is the strategic glue. As of 1 September 2026 the group has been split into three listed-or-to-be-listed pure plays: a green-chemicals company (IGL), an alcohol-beverage-plus-ethanol platform (IGL Spirits) and a plant-based API/nutraceutical company (Ennature Bio Pharma).
What the company does
Pre-demerger, IGL operated an integrated agro-to-ethanol-to-derivatives value chain. Molasses (purchased from sugar mills) and grain (rice, including Food Corporation of India allocations, and other cereals) are fermented and distilled into ethanol at Kashipur (Uttarakhand) and Gorakhpur (Uttar Pradesh). That ethanol — supplemented by domestically purchased and imported ethanol when economics favour it — is routed into three outlets:
-
Chemicals (BSPC): dehydration to bio-ethylene, oxidation to bio-EO, and conversion into bio-MEG/DEG/TEG, glycol ethers and acetates ("green solvents"), performance chemicals (oilfield chemicals, plasticisers, bio-based amines) and, historically, ethoxylates. Bio-EO derivatives (ethoxylates) were transferred to the Clariant IGL Specialty Chemicals JV in 2021, to which IGL now supplies EO under a long-term agreement. Industrial gases (oxygen, nitrogen, argon, CO₂) are produced from an air separation unit and the EO process CO₂ stream. Guar-based biopolymers (hydrocolloids) were also reported here.
-
Potable Spirits: Extra Neutral Alcohol (ENA) is bottled into branded country liquor (CL, also "IMIL") and Indian Made Foreign Liquor (IMFL), primarily for Uttar Pradesh and Uttarakhand; IGL also bottles for Bacardi under a 15-year relationship and markets Amrut brands in select North Indian markets.
-
Bio-Fuel: fuel-grade ethanol sold to Indian oil marketing companies (OMCs) under the national Ethanol Blended Petrol programme, plus distillers' grains (DDGS/DWGS) by-products. Reported as a separate segment from Q1 FY25 (previously within BSPC).
A fourth, smaller engine — Ennature Biopharma (Dehradun) — extracts plant-based APIs (global leader in thiocolchicoside, a muscle relaxant derived from Gloriosa seeds), natural nicotine and nicotine salts, and nutraceutical ingredients using supercritical CO₂ extraction.
Company's own description (paraphrased from FY26 investor materials)
IGL describes itself as one of India's leading manufacturers across BSPC, Bio-Fuel, Potable Spirits and Ennature Biopharma; the first company in the world to produce EO/MEG via the renewable molasses route (since 1989); exporting to more than 40 countries; offering 100+ green products from three integrated facilities spread over ~360 acres; with "green" positioned as core to its identity rather than a credential (Q4 FY26 Investor Presentation, May 2026). Management additionally claims, together with the Clariant JV, to be the world's largest supplier of bio-based speciality chemicals and the only at-scale producer of bio-based EO, glycols and glycol ethers (Q1 FY27 call, Aug 2026).
Business and revenue model
| Dimension | Characterisation |
|---|---|
| Revenue model | Overwhelmingly product sales (manufacturing). Minor service income from job-work/bottling (Bacardi), power sales from Gorakhpur cogeneration, ENA sales; royalty-paying (not royalty-earning) brand arrangement with Amrut. No meaningful subscription or licensing revenue. |
| Gross vs net revenue | Gross revenue includes state excise duty on potable spirits, which inflates the top line ~2.3x. FY26 gross ₹9,827 Cr vs net ₹4,211 Cr (Q4 FY26 presentation). Analysis should use net revenue. |
| Value-chain position | Vertically integrated from fermentation through to branded consumer goods (spirits) and intermediate/speciality chemicals (B2B). Upstream feedstock (molasses, grain) is bought; IGL does not grow cane, having exited sugar via the sale of Shakumbari Sugar and Allied Industries in 2023. |
| Customer types | B2B: global and Indian chemical, personal care, oil & gas, textile, automotive, packaging and pharma companies; OMCs (ethanol); the Clariant JV (EO offtake); Bacardi (bottling). B2C/B2G: state excise-regulated liquor distribution in UP/Uttarakhand/Delhi, Canteen Stores Department (CSD) and paramilitary canteens. |
| End-markets | Personal care, home care/detergents, oil & gas and refineries, automotive (coolants, brake fluids), textiles (MEG, glycol ethers), paints and coatings, agrochemicals, pharma/healthcare, food & beverage, packaging (PET via MEG), mining, metal working, pulp & paper, wastewater, alcoholic beverages, transport fuel. |
Independent characterisation
IGL is best understood as an ethanol arbitrage platform with three monetisation channels of very different quality. Potable spirits is the profit engine (FY26: 32% of net revenue, 52% of segment EBIT per the company's FY26 segment-share slide), protected by state licensing and by dominance in branded country liquor in UP/Uttarakhand. Bio-Fuel is a low-margin, policy-dependent volume outlet (FY26 EBIT margin 7.8%) that keeps distilleries loaded. Chemicals is a structurally challenged commodity business (bio-MEG competes against fossil MEG produced by Reliance and Middle Eastern exporters) that management is trying to pivot toward higher-margin "New Speciality" products (bio-amines, carbon-smart ethoxylates/glycols, green solvents). Historically the market applied a conglomerate discount; the demerger is explicitly designed to remove it. The key analytical tension is that the chemicals stub left in the listed IGL is the lowest-margin and least predictable piece, while the most valuable piece (spirits) now trades separately once IGL Spirits lists.
Strategy
Stated strategic themes (paraphrased from FY26 and Q1 FY27 materials)
Value unlocking via demerger: separate consumer (spirits) from B2B technology (chemicals) and life sciences, to attract dedicated investors, allow independent capital allocation, ring-fence risk and reduce the conglomerate discount.
Premiumisation in spirits: move up from country liquor to IMFL, Prestige & Above, and single malts via the Amrut partnership; focus on white spirits.
Specialty pivot in chemicals: shift from commodity glycols to performance chemicals, green solvents, bio-amines and carbon-smart products; "partner of choice" model with BASF, L'Oréal, Unilever and Mibelle (named by the CEO with permission).
3x3 feedstock flexibility: three ethanol sources (in-house, domestic purchase, import) feeding three outputs (fuel, chemicals, potable).
Deleveraging: FY26 preferential issue; IGL Spirits targeting debt-free status from FY28.
Innovation and sustainability: DSIR-approved R&D, LanzaTech C-smart collaboration, carbon-utilisation technologies (undisclosed).
Initiatives in the last 24 months
| Initiative | Date | Detail |
|---|---|---|
| Three-way demerger | Board May 2025; NCLT 17 Jul 2026; effective 1 Sep 2026 | Modified scheme after withdrawing KHL amalgamation |
| Share split 1:2 | Record date 12 Aug 2025 | Liquidity/affordability |
| Preferential equity issue | Allotted 24 Nov 2025 | ₹467 Cr for debt reduction and working capital |
| Bio-based amines commercialisation | First sales announced Aug 2025 | Approvals from global majors; L'Oréal anchor (per Arihant) |
| Amrut brand partnership | FY26 | Five Amrut brands in select North Indian markets |
| Single malt launch for North India | FY26 | Fusion Single Malt |
| CSD entry | FY26 | "Strong entry" reported; 3 brands approved, 1 pending |
| New state launches | Planned FY27 | Andhra Pradesh, Daman & Diu |
| Nicotine capacity | Q1 FY27 | Crude processing started at Kashipur |
| Ennature pipeline | Sep 2026 | One new API per year; dietary fibre entry |
| Leadership build-out | 2,026 | Spirits COO from ABD/Pernod; IR head |
ESG commitments with targets: no quantified emissions target located. Cost programmes with targets: none publicly quantified beyond capex discipline.
Management medium-term aspirations (explicitly described by management as aspirations, not projections — Q1 FY27 call)
| Entity | Metric | FY27 | 4–5 year aspiration |
|---|---|---|---|
| IGL Spirits | EBITDA (INR Cr) | above 500 | above 1,000 |
| IGL Spirits | IMFL volume | ~2x FY26 (3.4 mn cases) | Top-5 Indian alco-bev ambition |
| IGL Spirits | Leverage | — | Debt-free from FY28 |
| India Glycols (chemicals) | Revenue (INR Cr) | — | ~2,500 |
| India Glycols (chemicals) | EBITDA (INR Cr) | — | ~400 |
| New Speciality Unit | Revenue (INR Cr) | 150+ | 600–700; gross margin ~30% by ~2031–32 |
| India Glycols (chemicals) | Capex (INR Cr) | 5–20 | Modular; no large plant for ~2 years |
| Ennature Bio Pharma | EBITDA (INR Cr) | — | 130–150 |
Note: Investywise attributed the FY28 debt-free goal to IGL as a whole; the transcript attributes it to the IGL Spirits outlook. The ₹500 Cr FY27 EBITDA figure refers to IGL Spirits (₹120 Cr delivered in Q1).
Products & Services
Chemicals (BSPC; now India Glycols Ltd)
| Product line | Description / specification | Target customers | Notes |
|---|---|---|---|
| Bio-MEG (mono-ethylene glycol) | Ethylene glycol from bio-ethanol via bio-ethylene and bio-EO; IGL claims to be the only maker globally of bio-MEG, DEG and TEG from bio-ethanol | PET/polyester, textiles, coolants, packaging brands seeking bio-content | Commercial since 1989; repeated expansions 1995–2008; US-based Scientific Design technology partner for bio-glycols |
| Bio-DEG / Bio-TEG | Co-products of MEG plant | Unsaturated polyester resins, gas dehydration, plasticisers | Q1 FY27 glycols value +83% YoY |
| Bio-EO and high-purity EO | Ethylene oxide from bio-ethanol | Clariant IGL JV (long-term supply); internal derivatives | Q1 FY27: EO competitiveness vs Reliance improved due to crude spike |
| Glycol ethers and acetates ("green solvents") | Ethylene glycol monoethyl ether and acetates; IGL claims to be India's largest and only bio-glycol ether maker and only Indian producer using Sulzer Chemtech continuous technology | Paints & coatings, inks, crop protection, pharma, personal care, food | Q1 FY27 volumes +6%, value +13%, gross margins close to 50% (management) |
| Performance chemicals / New Speciality Unit (NSU) | Oilfield chemicals, plasticisers, rheology modifiers, metal-working and I&I cleaning chemicals | Oil & gas, refineries, automotive, metalworking | NSU Phase-I commissioned 2023; ~₹50–60 Cr invested in new plant; FY27 aspiration ₹150 Cr+ revenue; Q1 FY27 growth +40% |
| Bio-based amines | Described as world's first bio-based amines with approvals from global majors | Personal care (L'Oréal reported as anchor customer by Arihant) | First commercial sales announced Aug 2025 (Q1 FY26 presentation) |
| Carbon-Smart (C-smart) ethoxylates and glycols | Derived from ethanol produced from industrial emissions (LanzaTech technology) | Sustainability-led consumer brands | Management says IGL was the first company globally to supply these; volumes small |
| Industrial gases | Liquid oxygen, nitrogen, argon; industrial-grade CO₂ | Steel, healthcare, food & beverage | Global partnerships with Air Liquide and Praxair (technology); Q1 FY27 revenue ₹13 Cr at 23.1% EBITDA margin |
| Future pipeline | Bio-esters, speciality bio-amines, polygalactomannan derivatives, carbon-utilisation products | — | Management declines to quantify "transformational" carbon technologies |
Pricing model: spot and contract pricing; not publicly disclosed.
Biopolymers (formerly BSPC; now Ennature Bio Pharma Ltd)
| Product line | Description | Target customers | Notes |
|---|---|---|---|
| Guar gum and derivatives | Hydroxypropyl guar and PO-derivatised guar; IGL claims to be the only company globally with all types of standard and high-quality derived biopolymers (hydrocolloids) | Oil & gas fracturing, textiles printing, food, personal care | Guar gum plant since 2001; expansion 2015 |
Potable Spirits (now IGL Spirits Ltd)
| Brand / offering | Category | Detail (as disclosed) |
|---|---|---|
| Bunty Bubbly | Country liquor (branded CL) | 14 million cases sold in FY25; described by IGL as the highest-selling brand in India; Asia Book of Records and Limca Book of Records recognition |
| Amazing Vodka (Plain, Green Apple, Orange, imported flavours) | IMFL – flavoured vodka | Competes in a ~7 million case segment; gold medal at Spirits Selection |
| Zumba Lemon Vodka | IMFL – flavoured vodka | Double-digit share claimed in UP, Uttarakhand, Delhi, Chandigarh, paramilitary and CSD |
| Soulmate Blu / Soulmate Gin | IMFL | Described as a millionaire-case brand |
| Amazing Whisky Deluxe | IMFL – deluxe whisky | Launched into a ~36 million case segment |
| Single Reserve Whisky | IMFL – whisky | Listed in FY26 portfolio |
| V2O Orange Vodka | IMFL – vodka | Listed in FY26 portfolio |
| MaQintosh Whisky (Special Edition) | IMFL – Amrut partnership | Amrut legacy Karnataka brand acquired by IGL with new packaging; volume builder |
| MaQintosh White Label Whisky | IMFL – Amrut partnership | Launched by IGL for the semi-premium "belly" of the market (~12 million case segment) |
| Prestige Green Classic Whisky | IMFL – Amrut partnership | Bottled at Kashipur and Gorakhpur; IGL keeps manufacturing/marketing profit after a per-case royalty (~2.8 million case segment) |
| Fusion Single Malt | Luxury – Amrut flagship | Amrut flagship sold in 53 countries; IGL invests, distributes and markets in select North Indian markets; target 10,000+ cases |
| Amalgam | Premium blended malt – Amrut | Same distribution model |
| Bacardi brands (Carta Blanca, Limon, Breezer) | Contract bottling and supply chain | 15-year partnership; IGL Kashipur supplies North and East India; IGL says it is the only Indian partner with an exclusive Bacardi spirit-maturation facility |
| ENA (molasses and grain) | Bulk spirit | Captive plus third-party sales |
Volume data: IMFL FY26 3.4 million cases; Q1 FY27 IMFL 1.4 million cases (+55%), of which Prestige & Above ~0.5 million (~2x YoY); non-IMFL (CL) 7.5 million cases (+6%) with ₹279 Cr revenue. Management expects IMFL above 30% of PS revenue in FY27 and plans deluxe whisky, rum and semi-premium vodka launches plus defence (CSD) brand approvals (three approved, one pending) (Q1 FY27 call). Pricing: state excise-regulated MRPs; not otherwise disclosed.
Bio-Fuel (now IGL Spirits Ltd)
| Product | Description | Customers | Capacity |
|---|---|---|---|
| Fuel-grade ethanol | Special-grade ethanol for petrol blending | Indian OMCs under the EBP programme | Total ethanol capacities (incl. grain) 600 KLPD at Kashipur and 500 KLPD at Gorakhpur (shared with ENA/chemicals) |
| DDGS / DWGS | Distillers' dried/wet grains (animal feed) | Feed manufacturers | By-product |
| Power | Biomass cogeneration at Gorakhpur | Grid | Minor |
Ennature Biopharma (now Ennature Bio Pharma Ltd)
| Product line | Description | Notes |
|---|---|---|
| Thiocolchicoside | Muscle-relaxant API from Gloriosa superba seeds; IGL claims global leadership | Q1 FY27 sales +26% QoQ on price realisation; raw-material availability volatile |
| Natural nicotine and nicotine salts | Liquid nicotine for NRT and related uses | Sales doubled QoQ in Q1 FY27 on European customer conversions; crude processing started at Kashipur |
| Maxicuma | Nano-formulated curcumin with higher bioavailability | Branded nutraceutical |
| Lutein esters | Extracted with patented processes | Patents for lutein ester extraction cited |
| Phytochemicals / herbal extracts | Artemisia, stevia, rosemary, marigold, sage germplasm; contract farming with buy-back | Supercritical CO₂ extraction (SCFE), solvent, aqueous extraction, bio-fermentation |
| Pipeline | One new API per year; entry into dietary fibre; niche molecules | Announced at 2 Sep 2026 investor meet (Sahi/Fyers reports) |
Financial Narrative
All figures consolidated, ₹ Cr, from Q4 FY26 Investor Presentation (5-year trajectory and FY24–FY26 financial summary) unless marked "computed". FY22–FY23 detail below EBITDA and full balance sheets were not available in sources reviewed; cells left blank.
Income statement
Notes: Gross profit is not reported by IGL in the presentation format and is not publicly disclosed in sources reviewed. FY22 and FY23 reported PAT computed by adding back the exceptional items disclosed in the presentation footnote (₹221.34 Cr FY22; ₹28.13 Cr FY23) — the footnote does not state whether these are pre- or post-tax, so treat as approximate. EPS FY25 and FY26 are company-reported; FY22–FY24 computed as adjusted PAT ÷ 6.19 Cr split-adjusted shares. Standalone FY26: net revenue ₹4,211 Cr, EBITDA ₹690 Cr, PAT ₹282 Cr (includes ~₹39 Cr Clariant JV dividend in Q4).
Margins and growth
CAGRs (computed): net revenue FY22–FY26 10.1%; gross revenue FY22–FY26 10.5%; EBITDA FY22–FY26 23.9%; adjusted PAT FY22–FY26 25.3%. Company-stated FY24–FY26 CAGRs: net revenue 13.1%, EBITDA 23.6%, PAT 30.1%.
Commentary. The defining trend is five consecutive years of EBITDA margin expansion (9.6% to 15.5%), which management attributes to feedstock management, cost control, mix improvement and new businesses (Q1 FY27 call). The FY23 revenue dip reflects the transfer of the bio-EO derivatives business to the Clariant JV (deconsolidated from mid-2021) and weak glycol pricing. The FY24 inflection came from grain-based distilleries (commissioned 2022) which simultaneously enabled the Bio-Fuel business and cushioned ENA costs for spirits and chemicals. Below EBITDA, the story is less clean: depreciation rose 53% FY24–FY26 as new capacity came on stream, and finance costs stayed near ₹165 Cr in FY25–FY26, holding interest coverage below 3x. The JV contribution (₹46 Cr in each of FY25 and FY26) is a meaningful 12% of FY26 PBT.
Balance sheet
Goodwill and intangibles: not separately disclosed in the presentation format; not publicly disclosed in sources reviewed. Current assets computed as receivables + cash + inventory + other current assets; current liabilities as payables + short-term borrowings + other current liabilities.
Commentary. The balance sheet expanded ₹906 Cr in two years, driven by ₹1,274 Cr of fixed-asset growth (distilleries, NSU). FY25 marked peak leverage (net debt ₹1,727 Cr). The November 2025 preferential issue (₹467 Cr) plus a sharp ₹280 Cr inventory release in FY26 cut net debt by ~₹200 Cr and lifted equity to ₹2,933 Cr. However, the mix shifted toward short-term borrowings (₹919 Cr), which partly explains the persistently negative working-capital position. The Financial Express (via Askfuzz) reported that ~₹804 Cr of debt was prepaid in a single quarter after the issue — this figure was not reconciled with the year-end balance and should be treated as gross repayment rather than net reduction.
Cash flow
Note: the presentation labels the cash-flow table "₹ Mn" while the slide header states "Figures in ₹ Cr"; the magnitudes are consistent with ₹ Cr. Capex is not separately reported; investing cash flow is used as a capex proxy and includes investments. Dividends paid and buybacks are not separately disclosed in sources reviewed; IGL has not announced any buyback.
Commentary. FY26 operating cash flow more than doubled (+112%) to ₹769 Cr — management's headline cash metric — largely on working-capital release. Free cash flow was roughly break-even in FY26 after two years of heavy negative FCF, meaning deleveraging was funded by equity, not internal accruals. Management now guides to minimal chemicals capex (₹5–20 Cr in FY27), which, if sustained, should turn FCF clearly positive.
Ratios
First four rows company-reported; remaining rows computed (FY24 ROE/ROA/asset turnover use year-end values because FY23 balance sheet was unavailable). ROIC: not publicly disclosed; ROCE is the closest company metric.
Commentary. Returns are improving but remain modest for the risk profile: ROCE of 11.9% is likely below a reasonable pre-tax cost of capital for a mid-cap with A- credit. Leverage improved meaningfully in FY26 but a current ratio of 0.66 signals a working-capital structure dependent on rolling short-term bank lines — a point CARE has flagged in its rating sensitivities around liquidity buffers.
Latest quarter: Q1 FY27 (quarter ended 30 June 2026)
Sources: Multibagg, ScanX, Investywise reports of the 12 Aug 2026 results; Q1 FY27 call. Q1 FY26 EBITDA computed from reported growth (170/1.125); the CFO cited Q1 FY26 margin as 14.3% on the call while Multibagg reports 14.5% — minor discrepancy. Board approved results on 12 Aug 2026 after limited review.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Post-demerger home |
|---|---|---|
Bio-based Specialities & Performance Chemicals (BSPC) | Bio-glycols (MEG/DEG/TEG), glycol ethers & acetates (green solvents), bio-EO sales (incl. to JV), performance chemicals (oilfield, plasticisers, bio-amines), biopolymers/guar derivatives, industrial gases, ENA (per segment description) | Chemicals + gases stay in India Glycols Ltd; biopolymers move to Ennature Bio Pharma Ltd |
Potable Spirits (PS) | Branded country liquor (UP, Uttarakhand), IMFL, Bacardi bottling, ENA | IGL Spirits Ltd |
Bio-Fuel (BF) | Fuel ethanol to OMCs, DDGS/DWGS | IGL Spirits Ltd |
Ennature Biopharma (EB) | Plant-based APIs (thiocolchicoside), natural nicotine & salts, nutraceuticals, phytochemicals | Ennature Bio Pharma Ltd |
Potable Spirits | Uttar Pradesh, Uttarakhand (market leadership in branded CL), Delhi, Himachal Pradesh, Chandigarh; CSD/paramilitary nationwide | Planned launches in Andhra Pradesh and Daman & Diu (Q4 FY26); East India targeted for Amrut brands; Delhi growth dilutes margin vs Uttarakhand (Q1 FY27 call) |
Bio-Fuel | Domestic OMCs | Industry excess capacity; government considering higher blending (Q4 FY26) |
BSPC | India plus exports (Middle East, US, Europe) | Middle East oil & gas chemical exports collapsed and westbound freight rose 5–20x amid the 2026 regional conflict (Q1 FY27 call) |
Ennature | Global API and nicotine customers (Europe cited) | Nicotine conversions in Europe driving growth |
Segment net revenue (INR Cr)
| Segment net revenue (INR Cr) | FY24 | FY25 | FY26 |
|---|---|---|---|
BSPC net revenue (INR Cr) | — | 1,342 | 1,203 |
Potable Spirits net revenue (INR Cr) | — | 1,163 | 1,331 |
Bio-Fuel net revenue (INR Cr) | — | 1,044 | 1,470 |
Ennature Biopharma net revenue (INR Cr) | — | 219 | 208 |
Total net revenue (INR Cr) | 3,294 | 3,768 | 4,211 |
Segment EBIT (INR Cr)
| Segment EBIT (INR Cr) | FY25 | FY26 |
|---|---|---|
BSPC EBIT (INR Cr) | 125 | 141 |
Potable Spirits EBIT (INR Cr) | 256 | 285 |
Bio-Fuel EBIT (INR Cr) | 57 | 115 |
Ennature Biopharma EBIT (INR Cr) | 21 | 7 |
Segment EBIT margin (%)
| Segment EBIT margin (%) | FY24 | FY25 | FY26 |
|---|---|---|---|
BSPC EBIT margin (%) | — | 9.3 | 11.7 |
Potable Spirits EBIT margin (%) | — | 22.0 | 21.4 |
Bio-Fuel EBIT margin (%) | — | 5.4 | 7.8 |
Ennature Biopharma EBIT margin (%) | — | 9.5 | 3.5 |
Segment metric FY26 | BSPC | Potable Spirits | Bio-Fuel |
Net revenue YoY growth (%) | -10.4 | 14.4 | 40.9 |
EBIT YoY growth (%) | 12.5 | 11.1 | 103.3 |
Share of net revenue (%) | 29 | 32 | 35 |
Share of segment EBIT (%) | 26 | 52 | 21 |
Segment net revenue (INR Cr) (Quarterly)
| Segment net revenue (INR Cr) | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|---|
BSPC (INR Cr) | 254 | 300 | 288 | 313 | 301 | 363 |
Potable Spirits net (INR Cr) | 284 | 342 | 338 | 345 | 306 | 361 |
Bio-Fuel (INR Cr) | 273 | 348 | 423 | 394 | 305 | 323 |
Ennature Biopharma (INR Cr) | 52 | 51 | 43 | 50 | 63 | 83 |
Segment Revenue
| Pro-forma entity | Businesses | FY26 net revenue (INR Cr) | FY26 share (%) | Q1FY27 net revenue (INR Cr) | Q1FY27 EBITDA (INR Cr) | Q1FY27 EBITDA margin (%) |
|---|---|---|---|---|---|---|
India Glycols Ltd (listed) | Glycols, bio-glycols, glycol ethers, new speciality products, industrial gases | 1,163 | 28 | 345 | 40 | 11.6 |
IGL Spirits Ltd (to be listed) | IMFL, country liquor, ENA, Bio-Fuel | 2,801 | 67 | 694 | 120 | 17.3 |
Ennature Bio Pharma Ltd (to be listed) | Plant APIs, nicotine, nutraceuticals, bio-polymers | 247 | 6 | 90 | 10 | 11.1 |
Consolidated (pre-demerger) | All | 4,211 | 100 | 1,130 | 170 | 15.0 |
Income Statement and Per-Share Data
| Metric (INR Cr unless stated) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross revenue from operations (INR Cr) | 6,601 | 6,642 | 7,922 | 9,039 | 9,827 |
Net revenue, net of excise (INR Cr) | 2,868 | 2,651 | 3,294 | 3,768 | 4,211 |
Other income (INR Cr) | — | — | 26 | 15 | 5 |
EBITDA (INR Cr) | 277 | 319 | 428 | 525 | 654 |
Depreciation (INR Cr) | — | — | 101 | 115 | 155 |
EBIT (INR Cr) | — | — | 327 | 410 | 499 |
Finance cost (INR Cr) | — | — | 121 | 164 | 167 |
Share of JV profit (INR Cr) | — | — | 17 | 46 | 46 |
Profit before tax (INR Cr) | — | — | 223 | 292 | 377 |
Tax (INR Cr) | — | — | 50 | 61 | 84 |
Adjusted PAT, excl. exceptionals (INR Cr) | 119 | 113 | 173 | 231 | 293 |
Reported PAT incl. exceptionals, computed (INR Cr) | 340 | 141 | 173 | 231 | 293 |
Basic EPS, split-adjusted (INR) | 19.2 | 18.3 | 27.9 | 37.3 | 46.0 |
Dividend per share, split-adjusted (INR) | — | — | — | — | 7.5 |
Margin Analysis (%)
| Metric (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
EBITDA margin on net revenue (%) | 9.6 | 11.9 | 12.9 | 13.9 | 15.5 |
EBIT margin on net revenue, computed (%) | — | — | 9.9 | 10.9 | 11.8 |
Adjusted PAT margin (%) | 4.1 | 4.3 | 5.2 | 6.1 | 6.9 |
Net revenue YoY growth, computed (%) | — | -7.6 | 24.3 | 14.4 | 11.8 |
Gross revenue YoY growth, computed (%) | — | 0.6 | 19.3 | 14.1 | 8.7 |
Balance Sheet
| Balance sheet item (INR Cr) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Fixed assets (INR Cr) | 3,171 | 3,736 | 4,445 |
Capital work in progress (INR Cr) | 84 | 98 | 37 |
Investments incl. JV (INR Cr) | 335 | 381 | 389 |
Trade receivables (INR Cr) | 384 | 365 | 351 |
Inventory (INR Cr) | 1,106 | 1,171 | 891 |
Cash and bank balance (INR Cr) | 138 | 77 | 50 |
Total assets (INR Cr) | 5,617 | 6,176 | 6,523 |
Shareholders' funds (INR Cr) | 2,051 | 2,256 | 2,933 |
Long-term borrowings (INR Cr) | 725 | 1,040 | 659 |
Short-term borrowings (INR Cr) | 596 | 764 | 919 |
Total debt, computed (INR Cr) | 1,321 | 1,804 | 1,578 |
Net debt, computed (INR Cr) | 1,183 | 1,727 | 1,528 |
Trade payables (INR Cr) | 1,099 | 979 | 788 |
Working capital, current assets minus current liabilities, computed (INR Cr) | -430 | -505 | -776 |
Cash flow item (INR Cr)
| Cash flow item (INR Cr) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Cash flow from operations (INR Cr) | 439 | 362 | 769 |
Cash flow from investing (INR Cr) | -503 | -736 | -767 |
Cash flow from financing (INR Cr) | 90 | 354 | 23 |
Free cash flow proxy, CFO plus CFI, computed (INR Cr) | -64 | -374 | 2 |
Financial Ratios (x) and Returns & Leverage Ratios (%)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Debt to equity (x) | 0.59 | 0.68 | 0.64 | 0.80 | 0.54 |
Interest coverage, EBIT/finance cost (x) | 2.82 | 2.26 | 2.71 | 2.50 | 2.98 |
ROCE (%) | 7.5 | 7.7 | 10.5 | 11.6 | 11.9 |
Cash conversion cycle (days) | 60 | 59 | 43 | 64 | 45 |
ROE on average equity, computed (%) | — | — | 8.4 | 10.7 | 11.3 |
ROA on average assets, computed (%) | — | — | 3.1 | 3.9 | 4.6 |
Current ratio, computed (x) | — | — | 0.82 | 0.78 | 0.66 |
Net debt to EBITDA, computed (x) | — | — | 2.76 | 3.29 | 2.34 |
Asset turnover, net revenue/average assets, computed (x) | — | — | 0.59 | 0.64 | 0.66 |
Income Statement and Margin Analysis (%)
| Metric (INR Cr unless stated) | Q1FY26 | Q1FY27 | YoY change (%) |
|---|---|---|---|
Gross revenue from operations | 2,503.1 | 2,988.4 | 19.4 |
Net revenue | 1,040 | 1,130 | 8.6 |
EBITDA | 151 | 170 | 12.5 |
EBITDA margin (%) | 14.5 | 15.0 | — |
Finance cost | 45 | 25 | -44.4 |
Share of JV profit | 18.6 | 20.6 | 10.8 |
PBT | — | 102.6 | — |
PAT (consolidated) | 73.3 | 96.8 | 32.2 |
PAT (standalone) | — | 76.6 | 44.9 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansShare Price History
| Date | Price (INR) | Basis | Source |
|---|---|---|---|
30 May 2025 | 1,885.00 | Pre-split, FV ₹10 | Angel One |
17 Nov 2025 | 1,134.60 | Post-split intraday record high | Business Standard |
31 Mar 2026 | ~849 | Implied: ₹5,690.24 Cr ÷ 6.70 Cr shares (computed) | Q4 FY26 presentation |
10 Aug 2026 | 1,125.00 | Post-split, cum-demerger | Upstox |
1 Sep 2026 | 1,112.90 | Last cum-demerger close | Askfuzz/Business Today |
2 Sep 2026 | 229.85 open; 236.20 close | Ex-demerger, chemicals-only | Askfuzz; Fyers |
17 Sep 2026 | 266.95 | Ex-demerger | Anand Rathi |
Valuation Snapshot
| Multiple | Value | Basis / caveat |
|---|---|---|
P/E (pre-demerger) | ~22x | ~₹6,600 Cr valuation on trailing earnings around NCLT approval (Financial Express via Askfuzz, Jul 2026) |
EV/EBITDA (pre-demerger) | ~13x | Same source |
EV/Sales (pre-demerger, computed) | ~1.9x | (₹6,600 Cr + FY26 net debt ₹1,528 Cr) ÷ FY26 net revenue ₹4,211 Cr |
P/B (pre-demerger, computed at 31 Mar 2026) | ~1.9x | ₹5,690 Cr ÷ equity ₹2,933 Cr |
P/E (post-demerger, aggregator) | 21.29x | Anand Rathi, 17 Sep 2026 — basis unclear (likely mixes pre-demerger EPS); not reliable |
P/B (post-demerger, aggregator) | 2.01x | Same caveat |
Peer: Radico Khaitan | Share price ~₹4,348 (31 Jul 2026); FY26 PAT ₹605 Cr | — |
Analyst Ratings & Targets
| Broker | Note | View |
|---|---|---|
Arihant Capital | Q3 FY26 and Q4 FY26 result updates | SOTP-based target implying ~41.6% upside (Q4 FY26 note); exact target price not captured |
InCred Equities | Hosted Q1 FY27 call | Rating not disclosed |
Capital Markets
| Item | Detail |
|---|---|
Dividend FY26 | Interim ₹7.50 per ₹5 share |
Buybacks | None announced |
Credit rating | CARE A- (RWD) LT ₹1,229.79 Cr; CARE A- / A2+ (RWD) LT/ST ₹450 Cr; CARE A2+ (RWD) ST ₹850 Cr (6 Mar 2026). History: CARE A; Stable/A1 until 5 Mar 2024 downgrade. Moody's/S&P/Fitch: not rated |
Debt maturity | Not publicly disclosed in sources reviewed; FY26: long-term borrowings ₹659 Cr, short-term ₹919 Cr; allocation across the three entities post-demerger not yet disclosed |
Capital structure metric | FY2024 |
Shares outstanding, split-adjusted (Cr) | 6.19 |
Analyst Conclusions
Management guidance and consensus
Management has deliberately framed its targets as aspirations: IGL Spirits EBITDA above ₹500 Cr in FY27 (₹120 Cr achieved in Q1, i.e., a run-rate of ~₹480 Cr requiring acceleration) and above ₹1,000 Cr in four to five years with debt-free status from FY28; chemicals (continuing IGL) revenue of ~₹2,500 Cr and EBITDA of ~₹400 Cr in four to five years (versus FY26 pro-forma net revenue of ₹1,163 Cr); Ennature EBITDA of ₹130–150 Cr (versus Q1 FY27 annualised ~₹40 Cr). No formal sell-side consensus is available.
Bull case
-
Sum-of-the-parts re-rating: once IGL Spirits lists, a spirits-plus-ethanol platform with FY26 net revenue ₹2,801 Cr and Q1 FY27 EBITDA margin 17.3% could command alco-bev multiples well above the blended ~13x EV/EBITDA the group traded at pre-demerger.
-
Margin trajectory is structural: five straight years of EBITDA margin expansion (9.6% to 15.5%), finance costs nearly halved in a year, and capex now minimal suggest earnings can compound faster than revenue.
-
Optionality in green chemistry: a unique bio-EO/glycol platform, bio-amines with L'Oréal, and carbon-smart products give the continuing IGL a credible specialty story if NSU scales toward ₹600–700 Cr.
Bear case
-
The stub is the weakest piece: continuing IGL (chemicals and gases) earned only ~11.6% EBITDA margin in Q1 FY27 and its FY26 revenue fell; its competitiveness depends on elevated crude prices that may not persist.
-
Execution and allocation risk: listings of IGL Spirits and Ennature are still pending; debt allocation is undisclosed; CARE keeps ratings on watch. Shared-site operations at Kashipur create related-party complexity.
-
Aspirations look stretched: chemicals revenue must roughly double and Ennature EBITDA must rise ~3–4x; FY26 FCF was only ~break-even and the deleveraging relied on dilution.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | Why it matters |
|---|---|---|
| Listing and price discovery of IGL Spirits and Ennature Bio Pharma | Q3–Q4 FY27 (company indicated 1–3 months from record date per Askfuzz) | Determines SOTP value realisation |
| Disclosure of debt and asset allocation across three entities | With Q2 FY27 results (Nov 2026) | Credit rating resolution |
| CARE rating resolution | Post-allocation | Funding costs |
| Q2 FY27 results (first post-demerger quarter for IGL standalone) | Nov 2026 | Baseline for chemicals stub |
| IMFL volume run-rate vs doubling aspiration; new launches (deluxe whisky, semi-premium vodka), AP and Daman & Diu entry | Through FY27 | IGL Spirits ₹500 Cr EBITDA test |
| Crude oil and EO/MEG spreads | Continuous | Chemicals competitiveness |
| Ethanol blending policy beyond E20; OMC procurement prices | FY27 | Bio-Fuel margins |
| Customs second appeal on ₹33.43 Cr demand | Open | Contingent liability |
| Clariant JV milestone payments and dividends | Q4 FY27 | Cash to IGL |
| Index inclusion of new entities | On listing | Flows |
Analyst verdict
India Glycols has done what many Indian mid-cap conglomerates promise and few deliver: it has repaired its margins, cut leverage and broken itself up. The FY22–FY26 record is genuinely good — net revenue compounded ~10%, EBITDA ~24% and adjusted PAT ~25%, with EBITDA margin up nearly six points — and Q1 FY27 extended the run with record EBITDA of ₹170 Cr and PAT up 32%. The demerger, effective 1 September 2026, is the right answer to a persistent conglomerate discount, because the businesses have nothing in common except ethanol: a state-licensed consumer franchise, a policy-priced fuel business, a commodity-exposed chemicals platform and a niche botanical API maker.
The analytical consequence, however, is that "India Glycols" is now a different and smaller company. The continuing listed entity holds the chemicals and gases businesses — roughly 28% of FY26 net revenue, with low-teens EBITDA margins, recent revenue decline and a competitive position that improved in 2026 largely because of an exogenous crude spike. Its long-term aspiration (₹2,500 Cr revenue, ₹400 Cr EBITDA) is credible only if the New Speciality Unit and bio-amines scale with customers like L'Oréal and BASF; there is not yet enough disclosure to underwrite that.
The more compelling equity is likely to be IGL Spirits once listed: captive ENA, a dominant branded country-liquor franchise in two large states, accelerating IMFL volumes and Amrut-led premiumisation, with an explicit ₹500 Cr+ FY27 EBITDA aspiration. Ennature is an interesting option on a recovering nicotine and API business but is small.
Net verdict: constructive on the group's value-unlocking path, neutral-to-cautious on the continuing chemicals stub in isolation until (i) debt allocation and the CARE rating are resolved, (ii) Q2–Q3 FY27 confirm chemicals margins hold as crude normalises, and (iii) the two new entities list and trade. Investors should evaluate the three entities on a combined basis for at least the next two quarters.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Background / tenure | Compensation |
|---|---|---|---|
Uma Shankar (U.S.) Bhartia | Chairman & Managing Director; promoter | Re-appointed CMD for 5 years from 1 Apr 2021 (Feb 2021 filing) and again re-appointed by the Board on 16 May 2025; chairs the Clariant IGL JV; Kashipur Holdings group | — |
Rupark Sarswat | Chief Executive Officer | CEO tenure ~4.4 years (Simply Wall St) | ₹36.2 million total (Simply Wall St; breakdown not disclosed) |
Anand Singhal | Chief Financial Officer | — | — |
Ankur Jain | Head (Legal) & Company Secretary; Compliance Officer | — | — |
Manoj Kumar Rai | Executive Director & COO, IGL Spirits Ltd (Spirits and Ethanol) | 27 years' experience; B.Tech IIT Delhi, PGDM IIM Lucknow; former Chief Revenue Officer at Allied Blenders and Distillers; 19 years at Pernod Ricard India; earlier Marico, Saregama | — |
Akshay Bansal | Executive Director, Ennature Bio Pharma Ltd | — | — |
S.K. Shukla | Head, Liquor Business | — | — |
Gagan Kwatra | Head of Investor Relations (joined 2026) | ~15 years in IR/consulting incl. Jubilant FoodWorks, LT Foods, KPMG | — |
“—” = not publicly disclosed.
Board of Directors
| Name | Category | Notes |
|---|---|---|
U.S. Bhartia | Chairman & MD (Executive, Promoter) | Chairs CSR-type committee per NSE filing (chairperson since 14 Feb 2015 of the listed committee) |
Jayshree Bhartia | Non-Executive, Non-Independent | Director since 28 May 1999; spouse of CMD; holds 4,58,006 shares (0.68%) per MarketScreener (Nov 2025) |
Pragya Bhartia Barwale | Non-Executive, Non-Independent (from 12 Aug 2026; previously Whole-Time Director & KMP since 24 Jun 2020) | Daughter of CMD |
Alok Singhal | Listed as Executive Director by data providers (Arihant/Muthoot) | — |
Independent directors (per 2024–25 data-provider listings) | Pradip Kumar Khaitan, Jitender Balakrishnan, Ravi Jhunjhunwala, Jagmohan N. Kejriwal, Shukla Wassan, Ravi Kumar, Samrat Banerjee, Sushil Dutt Salwan | Some of these may have completed terms; verify against the latest Corporate Governance Report |
Major Shareholders
| Holder category | Stake (%) |
|---|---|
Promoter group (incl. Kashipur Holdings Ltd 49.77%) | 59.63 |
Foreign institutional investors | 2.27 |
Domestic institutions | 5.20 |
Public and others | 32.90 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Positioning vs IGL |
|---|---|---|
Glycols / EO (chemicals) | Reliance Industries | Dominant fossil MEG/EO producer in India; sets domestic EO price benchmark; IGL's bio-EO was at a cost disadvantage 2021–25 until the 2026 crude spike |
Glycols (imports) | Middle East producers (e.g., SABIC and regional crackers) | Low-cost MEG exporters into India; 2026 supply disruptions helped IGL |
Bio-based chemicals | Godavari Biorefineries | Closest Indian peer in ethanol-based chemicals; FY26 consolidated revenue ₹1,987.9 Cr; bio-based chemicals segment ₹578 Cr, PBIT ₹36 Cr |
Speciality chemicals / solvents | Laxmi Organic Industries, Jubilant Ingrevia | — |
Ethoxylates (via JV) | India Glycols' own JV with Clariant competes with other surfactant makers | — |
Potable Spirits (IMFL) | Radico Khaitan | Strong in UP; FY26 net revenue ₹6,050 Cr, EBITDA ₹1,018.5 Cr (16.8%); P&A 70% of IMFL value |
Potable Spirits (IMFL) | United Spirits (Diageo), Pernod Ricard India, Allied Blenders and Distillers | — |
Country liquor / IMIL + bulk alcohol | Globus Spirits | FY26 standalone revenue ₹3,621 Cr (+2.7%); P&A revenue ₹164 Cr; 15.7 mn regular cases |
Country liquor (UP/UK) | Associated Alcohols & Breweries, Tilaknagar (regional IMFL), other UP distillers | Regional rivals; IGL claims market leadership in branded CL in UP/UK |
Bio-Fuel | Balrampur Chini, Triveni Engineering, Gulshan Polyols, Godavari Biorefineries, Globus Spirits | Ethanol suppliers to OMCs; India now has excess capacity |
Ennature (APIs/nutraceuticals) | Sami-Sabinsa, Arjuna Natural, Synthite, Indena (thiocolchicoside), natural nicotine extractors | — |
Peer Comparison FY2026
| Metric | India Glycols (pre-demerger) | Radico Khaitan | Globus Spirits | Godavari Biorefineries |
|---|---|---|---|---|
Revenue (INR Cr) | 4,211 | 6,050 | 3,621 | 1,988 |
Revenue growth YoY (%) | 11.8 | 25 | 2.7 | 6.3 |
EBITDA margin (%) | 15.5 | 16.8 | — | — |
Net income (INR Cr) | 293 | 605 | — | — |
Recent Developments
--



